Palvella Therapeutics (PVLA) Cost of Revenue (2013 - 2014)
Palvella Therapeutics (PVLA) reported Cost of Revenue of $18.0 for Q3 2014, up 50.0% year-over-year from $12.0 in Q3 2013, and down 50.0% on a QoQ basis from $36.0 in Q4 2013.
Palvella Therapeutics (PVLA) has 2 years of Cost of Revenue data on file, last reported at $18.0 in Q3 2014.
- Quarterly Cost of Revenue rose 50.0% year-over-year to $18.0 in Q3 2014, while the trailing twelve-month figure through Sep 2014 was $66.0 (changed N/A YoY) and the FY2013 annual result came in at $36.0, changed N/A from the prior year.
- Cost of Revenue retreated to $18.0 in Q3 2014 per PVLA's latest filing, from $36.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $36.0 in Q4 2013 and bottomed at $12.0 in Q3 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 18.00 |
| Sep 30, 2014 | 18.00 |
| Dec 31, 2013 | 36.00 |
| Dec 31, 2013 | 36.00 |
| Sep 30, 2013 | 12.00 |
| Sep 30, 2013 | 12.00 |